Background {#Sec1}
==========

Chronic suppurative otitis media (CSOM) is defined as chronic inflammation of the middle ear in presence of the tympanic membrane perforation and discharge/otorrhoea for more than 6 weeks to 3 months \[[@CR1], [@CR2]\]. Chronic suppurative otitis media constitutes a major public health problem worldwide and it is associated with high morbidity \[[@CR3]\]. Its incidence in developing countries is as high as 46 % and is common in children with low social economic status \[[@CR4], [@CR5]\]. Due to poor health seeking behavior and unavailability of ear, nose and throat (ENT) in primary health services, majority of these patients presents late to the tertiary hospitals \[[@CR6], [@CR7]\]. Chronic suppurative otitis media has been documented to be the commonest cause of preventable hearing loss \[[@CR8]--[@CR12]\]. *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Proteus mirabilis*, *Klebsiella pneumonia* and *Escherichia coli* have been found to be the commonest isolates causing CSOM in many studies \[[@CR13], [@CR14]\].

Despite the fact that CSOM constitutes a major cause of ENT clinic visits in Tanzania, little is known regarding disease complications, treatment outcome, spectrum of pathogens and their susceptibility pattern \[[@CR15]\]. Lack of treatment guidelines and information regarding predictors of disease in most centres in developing countries like Tanzania make the management of CSOM more challenging. Hence, this study was performed in order to provide predictors of disease complications and poor treatment outcome, local data on aetiology and susceptibility pattern that will help in policy formulation and reduction of morbidity and mortality associated with CSOM.

Methods {#Sec2}
=======

This was prospective hospital based cross sectional study conducted between October 2013 and March 2014 at ENT and surgical wards of the Bugando Medical Centre (BMC). The ENT clinic at BMC attends 632 patients annually. The protocol to conduct this study was approved by the Joint CUHAS/BMC Research, Ethics and publication committee.

All patients aged more than one year who presented with ear discharge for more than 6 weeks and tympanic membrane perforation were included into the study. All patients on topical ear antibiotics for 5 days or more at ENT clinic and surgical wards were excluded. All recruited patients were managed according to the routine treatment protocol of BMC and followed for 14 weeks.

The diagnosis of CSOM and its complications was confirmed by history taking to elicit the symptoms of ear problem like ear pain, ear discharge and duration of discharge \[[@CR16]\]. Physical examination (otoscopic examination for verification of discharge and tympanic perforation as well as tuning fork examination --Rinne's test and Weber's test for assessment of hearing loss) were performed as previously described \[[@CR1]\].

Specimen collection and processing {#Sec3}
----------------------------------

Pus was aseptically collected using sterile cotton swabs (Heinz Herenz Hamburg, Germany) and transported to the laboratory using Stuart transport media (HiMedia Laboratories Pvt. Ltd, Mumbai, India) within an hour of collection.

The specimens were inoculated on Chocolate, blood and MacConkey agar plates (Oxoid, Basingstoke Hampshire RG24 8PW, UK). The culture plates were incubated (aerobically) at 37 °C for 24--48 hours before colonial morphologies were interpreted \[[@CR17]\]. In house biochemical tests (catalase, coagulase, DNase, citrate, triple sugar iron agar, oxidase, urease, sulphur, indole and motility all from HiMedia, India) were performed to identify the isolates \[[@CR17]\]. In case of ambiguous results, commercial available biochemical tests API 20E and API 20NE (Biomerieux, Marcy l'Etoile, France) were used for the confirmation. Susceptibility testing was performed following CLSI 2011 guidelines \[[@CR18]\]. The following antibiotics were used: ciprofloxacin (CIP) 5 μg, trimethoprim**/**sulphamethoxazole (SXT) 1.25/23.75 μg, gentamicin (CN/GEN) 10 μg, ampicillin (AMP) 10 μg, vancomycin (VA) 30 μg, erythromycin (E) 15 μg, tetracycline 30 μg (Oxoid, UK) and cefoxitin (30 μg) to detect MRSA for gram positive bacteria while for gram negative bacteria ciprofloxacin (CIP) 5 μg, trimethoprim/sulphamethoxazole (SXT) 1.25/23.75 μg, gentamicin (CN/GEN) 10 μg, meropenem (MEM) 10 μg, amoxicillin/clavulanic acid (AMC) 20/10 μg, ceftriaxone (CRO) 30 μg and ceftazidime (CAZ) 30 μg (Oxoid, UK) were tested. Extended spectrum beta lactamases (ESBL) producing bacteria was detected as described previously \[[@CR17]\].

HIV testing {#Sec4}
-----------

After provider initiated counselling and testing (PICT), HIV testing was performed using Tanzania National Rapid test algorithms protocol \[[@CR19]\]. CD4 count was performed using FACS CALIBUR (BD Biosciences, USA), to all patients who were found to be HIV positive to determine severity of immune suppression.

Patient's management {#Sec5}
--------------------

On admission all patients were screened for diseases complications (Unfavorable evolution of a disease) such as hearing loss, mastoditis and intracranial infections. All patients suspected with mastoid bone osteomyelitis were investigated using plain film radiography of mastoid region. For these patients with chronic mastoiditis surgical management was added on top of conservative management which was done to the rest of patients. The conservative management involved ear wicking and use of topical antimicrobial agents based on BMC treatment guidelines which advocate the ciprofloxacin ear drops and boric acid drops while surgical management included surgical debridement/mastoidectomy and incision & drainage. All patients were followed on clinic visits of once per month for 14 weeks to determine treatment outcome as evidenced by persistence of ear discharge. In some cases phone calls were done to ascertain the progress after 14 weeks. In the second visit ear drops were changed based on culture and sensitivity results.

Statistical data analysis {#Sec6}
-------------------------

Data analysis was done using STATA version 11. Data were summarized in form of proportions, frequent tables and bar graph for categorical variables. Means (standard deviation) and median (inter quartile range) were used to summarize continuous variables. Univariate followed by multivariate logistic regression analysis were done to determine predictors of treatment outcome. Predictors investigated included; illness duration, age, sex, type of isolates, susceptibility pattern, smoking, HIV status, smell of discharge, otalgia and ear involved. Odds ratios with respective 95 % confidence interval (CI) were reported. Predictors with a p-value of less than 0.05 were considered statistically significant.

Results {#Sec7}
=======

Patients characteristics {#Sec8}
------------------------

A total of 301 patients with CSOM were studied, their mean age was 33.7 ± 17.9 years. Of the studied population 165 (54.8 %) were females (Table [1](#Tab1){ref-type="table"}). Majority of patients 115 (38.2 %) in this study were small scale farmers, followed by students 65 (21.6 %) and the rest were employed (Table [1](#Tab1){ref-type="table"}). Out of 301 patients, 155 (51.5 %) came from rural areas and 146 (48.5 %) from urban areas. Among the study participants; 24 (8.0 %) patients presented with history of pre morbid illness, of which diabetes were reported in 22/24 (92 %) and cancer in 2 (0.7 %). Out of 301 participants, 13 (4.3 %) were found to be HIV positive (Table [2](#Tab2){ref-type="table"}).Table 1Demographic characteristics of patientsPatients' characteristicNumber of patients(%)Sex Female16554.8 Male13645.2Age (years) 1--103110.30 11--205217.28 21--305116.94 31--405919.60 41--505518.27 \>503317.61Occupation Business5317.61 Students6521.59 Peasants11538.21 Public servants4916.28 NA/children196.31Education level Pre primary237.64 Primary12842.52 Secondary11036.54 Tertiary3712.29 No formal education31.00Residency Rural15551.5 Urban14648.5Smoking Yes4113.62 No26086.38HIV status Positive134.32 Negative27792.03 Refused to test113.65Co-morbidity Yes248.0 No27792.0Table 2Distribution of clinical presentation in the study populationPatients' characteristicNumber of patients(%)Ear affected Right16153.49 Left12240.53 Bilateral185.98Duration of illness/months 0--66621.93 7--125718.94 13--2412340.86 25--364414.62 \>36113.65Presenting symptoms Smell3411.33 Otalgia13444.82 Itching7424.58 Tinnitus9732.23  ^a^Others51.66^a^Vertigo 3, irritability 1, Nasal discharge 1

At the time of enrolment, 114 (37.9 %) of patients had hearing loss (99 conductive, 4 sensory neural and 11 mixed) and 5 (1.7 %) had mastoiditis. All patients with mastoiditis also had conductive hearing loss.

All patients were treated conservatively, 16 (5.3 %) surgical debridement was added and 5 (1.7 %) also underwent mastoidectomy.

Isolates and susceptibility pattern {#Sec9}
-----------------------------------

Out of 301 patients with CSOM, 187 (62.1 %) had positive aerobic culture within 48 h of incubation. Of these gram negative bacteria 116 (61 %) formed majority of isolates predominated by *Pseudomonas* spp. 56 (29.5 %) Table [3](#Tab3){ref-type="table"}. Of 36 gram positive bacteria; 34 (94 %) were identified as *Staphylococcus aureus* with 14 (41 %) identified as methicillin resistant *Staphylococcus aureus* (MRSA). *Pseudomonas* spp. were 52, 47, 9, 2 and 0 % resistant to amoxicillin/clavulanic acid, ceftazidime, gentamicin, meropenem and ciprofloxacin respectively Table [3](#Tab3){ref-type="table"}. Of 116 g negative enteric bacteria, 49 (42 %) were found to be ESBL.Table 3Resistance profile of bacterial isolates in the study populationBacterial isolateEVASXTTECIPGENCAZAMCCROMEMAMPPseudomonas spp. (56)\--0 %9 %47 %95 %2 %100 %S. aureus (34)31 %3 %74 %6 %4 %11 %\-\-\--Proteus spp. (27)\-\-\--0 %4 %8 %70 %7 %4 %100 %E. coli (22)\-\--67 %10 %53 %70 %90 %70 %0 %91 %\* Other gram negative (13)\--75 %3233 %63 %67 %50 %75 %25 %100 %E, VA, OX were tested for gram positive bacteria and GEN, CIP, AMC were tested for both gram positive and gram negative bacteria and CAZ, MEM, CRO were tested for gram negative bacteriaAbbreviation: AMC, AMP CAZ, CRO, E, GEN, CIP, SXT, TE, OX, VA and MEM stand for amoxicillin/clavulanic acid, ampicillin, ceftazidime, ceftriaxone, erythromycin, gentamicin, ciprofloxacin, trimethoprim/sulphamethoxazole, tetracycline, oxacillin, vancomycin and meropenem respectively\*Other gram negative: *Klebsiella* spp. (8), *Acaligenesis* spp. (4) and *Acinetobacter* spp. (1)

Factors predicting disease complications {#Sec10}
----------------------------------------

Disease complications were observed in 114/301 (37.8 %, 95 % CI; 32.2--43.3) patients. Conductive hearing loss was the commonest 99 (86.8 %) complication observed. Of 288 patients with negative HIV sero-status, 105 (36.4 %) had disease complications compared to 9 (69.2 %) of 13 patients with positive HIV sero-status (*p* = 0.028). It was also observed that as illness duration increases by one month the risk of getting disease complications increases by 3 %. On multivariate logistic regression analysis increase in illness duration (OR 1.03, 95 % CI; 1.007--1.05; *p* = 0.01), being infected by multi drug resistant bacteria (OR 1.86, 95 % CI; 1.04--3.3; *p* = 0.035), being HIV positive (OR 4.3, 95 % CI; 1.17--15.6; *p* = 0.028) and otalgia (OR 1.9, 95 % CI; 1.14--3.18; *p* = 0.013) were independently factors found to predict disease complications Table [4](#Tab4){ref-type="table"}.Table 4Factors predicting complications of CSOMVariableUnivariateMultivariateComplication n (%)OR (95 % CI)P valueOR (95 % CI)P valueAge35 ± 17.821.006 (0.99--1.011)0.3181.006 (0.997--1.02)0.443Sex Female (165)66 (40)1 Male (136)48 (35.3)0.81 (0.511--1.3)0.4020.88 (0.49--1.55)0.679Occupation No (199)31 (15.6)1 Yes (102)15 (14.7)0.93 (0.47--1.8)0.8420.8 (0.37--1.7)0.568Ill duration18 IQR (9--27)1.029 (1.008--1.05)0.0051.03 (1.007--1.05)0.010Isolates NBG (175)67 (38.29)1 GPB (35)21 (60)2.41 (1.15--5.07)0.02 GNB (91)45 (49.45)1.57 (0.94--2.63)0.081MDR No (229)81 (35.6)1 Yes (72)33 (45.8)1.54 (0.90--2.6)0.1121.86 (1.044--3.3)0.035HIV No (288)105 (36.4)1 Yes (13)9 (69.2)3.92 (1.17--13.)0.0264.3 (1.17--15.6)0.028Smoking No (260)100 (38.5)1 Yes (41)14 (34.2)0.83 (0.415--1.6)0.5970.80 (0.339--1.88)0.611Smell No (267)98 (36.7)1 Yes (34)16 (47.1)1.53 (0.747--3.4)0.2441.62 (0.73--3.56)0.234Otalgia No (167)52 (31.1)1 Yes (134)62 (46.301.98 (1.2--3.05)0.0071.9 (1.14--3.18)0.013Itching No (227)90 (39.6)1 Yes (74)24 (32.4)0.7 (0.412--1.27)0.2670.66 (0.359--1.24)0.205Ear Left (122)41 (33.6)1 Both (18)13 (72.2)5.13 (1.7--15.4)0.003 Right (161)60 (37.2)1.17 (0.72--1.92)0.5251.07 (0.82--1.40)0.573NBG is no bacterial growth, GNB is gram negative bacteria, GPB is gram positive bacteria and MDR is multi drug resistance bacteriaIsolates were not analysed on multivariate logistic regression analysis because it has collinearity with other factor like MDR

Factors predicting poor treatment outcome {#Sec11}
-----------------------------------------

In the current study poor treatment outcome defined by persistent otorrhoea was observed in 46 (15.3 %, 95 % CI; 11.2--19.3) of patients. Of HIV negative patients 38 (13.2 %) had poor treatment outcome compare to 8 (61.5 %) of HIV positive patients *p* \< 0.001. Out of 134 patients with otalgia, 28 (20.9 %) had poor treatment outcome compared to 18/167 (10.8 %) of those without otalgia (*p* = 0.01) On multivariate logistic regression analysis being infected by multi drug resistant bacteria (OR 3.6, 95 % CI; 1.7--7.59; *p* = 0.001), being HIV positive (OR 11.8, 95 % CI; 3.24--43.1; *p* \< 0.001) and otalgia (OR 3.3, 95 % CI; 1.56--7.02; *p* = 0.002) were independently factors found to predict poor treatment outcome Table [5](#Tab5){ref-type="table"}.Table 5Factors predicting poor treatment outcome of CSOMVariableUnivariateMultivariateOtorrhoea: n (%)OR (95 % CI)P valueOR (95 % CI)P valueAge34.42 ± 18.041.004 (0.98--1.019)0.8771.001 (0.97--1.02)0.956Sex Female (165)21 (12.7)1 Male (136)25 (18.4)1.5 (0.82--2.9)0.1771.47 (0.66--3.2)0.399Occupation No (199)31 (15.6)1 Yes (102)15 (14.7)0.93 (0.47--1.8)0.8420.8 (0.37--1.7)0.568Ill duration18 IQR (9--24)1.0087 (0.98--1.04)0.5070.99 (0.96--1.027)0.797Isolates NBG (175)67 (38.29)1 GPB (35)21 (60)2.41 (1.15--5.07)0.02 GNB (91)45 (49.45)1.57 (0.94--2.63)0.081MDR No (229)27 (11.8)1 Yes (72)19 (26.4)2.68 (1.38--5.1)0.0033.6 (1.7--7.59)0.001HIV No (288)38 (13.2)1 Yes (13)8 (61.5)10.5 (3.2--33.8)0.00011.8 (3.24--43.1)0.000Smoking No (260)37 (14.2)1 Yes (41)9 (21.9)1.7 (0.74--3.8)0.2061.08 (0.37--3.14)0.883Smell No (267)38 (14.2)1 Yes (34)6 (23.5)1.85 (0.78--4.39)0.272 (0.74--5.69)0.164Otalgia No (167)18 (10.8)1 Yes (134)28 (20.9)2.18 (1.49--3.8)0.0173.3 (1.56--7.02)0.002Itching No (227)30 (13.2)1 Yes (74)16 (21.6)1.8 (0.92--3.55)0.0841.82 (0.81--4.10)0.144Ear Left (122)18 (14.7)1 Both (18)1 (5.56)0.3 (0.04--2.7)0.309 Right (161)27 (16.77)1.1 (0.60--2.2)0.6461.08 (0.74--1.58)0.658NBG is no bacterial growth, GNB is gram negative bacteria, GPB is gram positive bacteria and MDR is multi drug resistance bacteria. Isolates were not analysed on multivariate logistic regression analysis because it has collinearity with other factor like MDR

Discussion {#Sec12}
==========

Demographic and clinical presentations {#Sec13}
--------------------------------------

In the current study, though not statistically significant CSOM was a common problem in third and fourth decades of life. Similar results were reported in University hospitals in Singapore by Loy et al. \[[@CR20], [@CR21]\] in Nepal. This could be explained by a possibility of persistence silent disease and failure to present early to hospital with ENT services as previously reported \[[@CR22]--[@CR24]\] and confirmed in this study.

Predictors of disease complication and poor treatment outcome {#Sec14}
-------------------------------------------------------------

HIV seropositive among patients with CSOM has been reported to be associated with severe disease and poor treatment outcome \[[@CR23], [@CR25]\]. This has been confirmed in the current study whereby HIV positive patients were 4.3 and 11.8 times more to have disease complications and poor treatment outcome than HIV negative patients. Though not statistically significant in this study, patients who were smoking had 8 % more chance to have poor treatment outcome than non-smokers. The influence of smoking has been documented previously \[[@CR8], [@CR22]\] and this could be due to the fact that smoking cause irritations to nasal passage causing thickening of nasal mucosa with mucous which favours bacteria growth. Also smoking has been proven to weaken immune system hence recurrent upper respiratory tract infections including otitis media \[[@CR26]\].

This study confirms what has been documented previously regarding the contribution of prolonged illness duration in bringing disease complication such as conductive hearing loss \[[@CR8], [@CR27]\]. Prolonged illness duration can be due to ignorance, treatment at home, cost, poverty and mainly poor infrastructures as long as ENT services are concerned in many developing countries such as Tanzania.

Other factors found independently to predict disease complications and poor treatment outcome were otalgia and infection due to multi drug resistant bacteria. The presence of otalgia could explain severe inflammation associated with extensive pathology leading to persistence of the pathology even after treatment. More extensive management and prolonged treatment might be necessary in patients with otalgia. Invasive infections with multi drug resistant pathogens have been found to be associated with increased morbidity and mortality \[[@CR28]\]. In the present study patients infected with multi drug resistant pathogens were 1.86 and 3.6 times more likely to have disease complications and poor treatment outcome than those infected with sensitive bacteria. These findings underscore the importance of empirical treatment derived from local susceptibility data.

Pathogens and susceptibility patterns {#Sec15}
-------------------------------------

In the present study bacterial growth rate was lower compared to previously studies done in Ethiopia, Philippines, Nigeria, Kenya and India \[[@CR3], [@CR11], [@CR12], [@CR24], [@CR29]\] respectively. The relatively low culture positive rate in this study could be due to prior use of antibiotics and inability to perform anaerobic culture.

As documented previously \[[@CR15], [@CR29], [@CR30]\] in the present study gram negative bacteria formed majority of isolates, predominated by *Pseudomonas* spp. Natural habitat, minimum nutritional requirement and ability to colonize moist areas of the body support our findings \[[@CR31]\].

*Pseudomonas* spp. isolated in our study were all susceptible to ciprofloxacin and 91 % sensitive to gentamicin; these results still give assurance on the usefulness of these agents as effective first line topical antibiotics in treatment for CSOM. In contrast to *Pseudomonas* spp. isolated from wounds in the same hospital these isolates are generally more sensitive. This could be due to the fact that patients from this study were coming from the community and those in previous study were from hospital \[[@CR32]\]. Hospital isolates have been found to be more resistant than community isolates \[[@CR18]\]. Methicillin Resistant *Staphylococcus aureus* (MRSA) was detected in 41 % which concurs with studies undertaken previously in Nigeria \[[@CR33], [@CR34]\]. As limitation, some pathogens observed in this study might not be the true cause of the pathology because of the chronic nature of the process leading to the pathology.

Conclusions {#Sec16}
===========

CSOM due to multi drug resistant bacteria is common in our setting. Majority of patients with prolonged illness duration, otalgia, infected with multi drug resistant bacteria and those with positive HIV status poorly respond to treatment and tend to present with disease complications. Guidelines for management of CSOM in developing countries are needed so that associated complications can be reduced.
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